Author pages are created from data sourced from our academic publisher partnerships and public sources.
Chemotherapy and the war on cancer
The era of chemotherapy began in the 1940s with the first uses of nitrogen mustards and antifolate drugs. Cancer drug development since then has transformed from a low-budget, government-supported… Expand
Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials.
CONTEXT In the past, cancer patients entering phase 1 studies confronted the prospects of high risk and unlikely benefit. Over the last decade, cancer drugs under development have become more… Expand
Polyglutamation of methotrexate. Is methotrexate a prodrug?
- B. Chabner, C. Allegra, +5 authors J. Jolivet
- Biology, Medicine
- The Journal of clinical investigation
- 1 September 1985
La polyglutamation est assuree par la folyl polyglutamyl synthetase. Leur etude decrit l'importance pharmacologique de la polyglutamation du methotrexate
The National Cancer Institute: cancer drug discovery and development program.
The discovery and development of novel therapeutic products for the treatment of malignancy is vitally important to those physicians responsible for the management of cancer patients. A description… Expand
Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers.
- W. Wilson, K. Dunleavy, +9 authors J. Janik
- Journal of clinical oncology : official journal…
- 1 June 2008
PURPOSE To assess the clinical outcome and the influence of biomarkers associated with apoptosis inhibition (Bcl-2), tumor proliferation (MIB-1), and cellular differentiation on the outcome with… Expand
Cancer Chemotherapy and Biotherapy: Principles and Practice
Clinical Strategies for Cancer Treatment: The Role of Drugs Preclinical Aspects of Cancer Drug Discovery and Development Pharmacokinetics and Clinical Monitoring Infertility after Cancer Chemotherapy… Expand
The pharmacology and clinical use of methotrexate.
- J. Jolivet, K. Cowan, G. Curt, N. Clendeninn, B. Chabner
- The New England journal of medicine
- 3 November 1983
METHOTREXATE, the most widely used antimetabolite in cancer chemotherapy, has an essential role in the treatment of such diverse diseases as acute lymphocytic leukemia, non-Hodgkin's lymphoma, oste...
Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy.
We hypothesized that incremental improvements in the cyclophosphamide-doxorubicin-vincristine-prednisone (CHOP) chemotherapy regimen through optimization of drug selection, schedule, and… Expand
Inhibition of phosphoribosylaminoimidazolecarboxamide transformylase by methotrexate and dihydrofolic acid polyglutamates.
- C. Allegra, J. Drake, J. Jolivet, B. Chabner
- Chemistry, Medicine
- Proceedings of the National Academy of Sciences…
- 1 August 1985
We report the enhanced inhibitory potency of methotrexate (MTX) polyglutamates and dihydrofolate pentaglutamate on the catalytic activity of phosphoribosylaminoimidazolecarboxamide (AICAR)… Expand
Commentary on Clinical Safety of Recombinant Human Parathyroid Hormone 1‐34 in the Treatment of Osteoporosis in Men and Postmenopausal Women
RECOMBINANT HUMAN parathyroid hormone 1-34 [rhPTH(1–34)], currently under the Food and Drug Administration (FDA) review for marketing approval as FORTEO (teriparatide injection [rDNA origin]), is a… Expand